Meanwhile, sales of GSK’s long-acting injected HIV treatment Cabenuva were at 458 million pounds ($596 million), which were up 51% year over year. The company has projected sales of its HIV ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

and a contribution by recently-launched long-acting injectable Cabenuva (cabotegravir). On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £ ...

GSK plc GSK reported third-quarter 2024 core earnings of $1.27 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.16. Core earnings declined 1% year over year on a ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

GSK managed to beat analysts’ revenue predictions for the first quarter of the year, despite an 8% decline in turnover pegged back by declines in COVID-19-related products. The group posted £6. ...

GSK is delivering consistent financial performance ... more than 50% of total growth for the quarter and year-to-date. Cabenuva grew 40%, driven by patient preference and proven and durable ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

GSK plc GSK reported third-quarter 2024 core ... JNJ-partnered Juluca — and long-acting medications — Apretude and Cabenuva. The combined revenues from these four drugs contributed nearly ...